Novavax (NASDAQ:NVAX) Stock Passes Above Two Hundred Day Moving Average of $0.00

Novavax, Inc. (NASDAQ:NVAX)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $4.47. Novavax shares last traded at $4.40, with a volume of 2,305 shares.

NVAX has been the subject of several analyst reports. ValuEngine cut Novavax from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. HC Wainwright reaffirmed a “positive” rating and issued a $12.00 price objective (up from $10.00) on shares of Novavax in a report on Monday, July 1st. Chardan Capital reaffirmed a “neutral” rating and issued a $7.00 price objective on shares of Novavax in a report on Friday, May 10th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Novavax in a report on Thursday, May 9th. Finally, Oppenheimer lifted their price objective on Novavax from $1.25 to $25.00 in a report on Monday, May 13th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $40.20.

The company’s 50-day moving average price is $5.04. The company has a market cap of $101.17 million, a PE ratio of -0.43 and a beta of 2.24.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.20) EPS for the quarter, topping the consensus estimate of ($2.40) by $0.20. The company had revenue of $3.98 million during the quarter, compared to analysts’ expectations of $4.80 million. During the same period last year, the company earned ($2.80) earnings per share. As a group, sell-side analysts anticipate that Novavax, Inc. will post -5.77 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in NVAX. Millennium Management LLC grew its holdings in Novavax by 127.8% during the fourth quarter. Millennium Management LLC now owns 2,934,275 shares of the biopharmaceutical company’s stock valued at $5,399,000 after purchasing an additional 1,645,934 shares during the period. Edmond DE Rothschild Holding S.A. grew its holdings in Novavax by 86.7% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 1,537,130 shares of the biopharmaceutical company’s stock valued at $847,000 after purchasing an additional 713,752 shares during the period. Two Sigma Advisers LP grew its holdings in Novavax by 39.4% during the fourth quarter. Two Sigma Advisers LP now owns 1,696,849 shares of the biopharmaceutical company’s stock valued at $3,122,000 after purchasing an additional 479,387 shares during the period. SG Americas Securities LLC grew its holdings in Novavax by 3,799.2% during the first quarter. SG Americas Securities LLC now owns 435,107 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 423,948 shares during the period. Finally, Creative Planning grew its holdings in Novavax by 161.7% during the first quarter. Creative Planning now owns 513,324 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 317,204 shares during the period.

About Novavax (NASDAQ:NVAX)

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Recommended Story: Options Trading – Understanding Strike Price

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.